Wilma
Wilma Dormeyer, Muenchen DE
Patent application number | Description | Published |
---|---|---|
20100081796 | BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES - The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies. | 04-01-2010 |
20120149879 | BISPECIFIC ANTI-EGFR/ANTI-IGF-1R ANTIBODIES - The present invention relates to bispecific antibodies against EGFR and against IGF-1R, methods for their production, pharmaceutical compositions containing said antibodies, and methods of treatment using the antibodies. | 06-14-2012 |
20120269723 | COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT - The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof. | 10-25-2012 |
20120282280 | BI-SPECIFIC DIGOXIGENIN BINDING ANTIBODIES - This invention relates to bispecific antibodies and antibody fragments against a target protein and a hapten, wherein the hapten is PEG or biotin, most preferably digoxigenin, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical 5 compositions containing said antibodies, and uses thereof. | 11-08-2012 |
20140135482 | Bispecific Anti ErbB3 / Anti cMet Antibodies - The present invention relates to bispecific antibodies against human ErbB-3 and against human c-Met, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof. | 05-15-2014 |
Wilma Kraft-Weyrather, Darmstadt DE
Patent application number | Description | Published |
---|---|---|
20090274273 | Irradiation Verification Device for Radiotherapy Installations, and Method for Handling Thereof - The present invention relates to an irradiation verification apparatus ( | 11-05-2009 |
Wilma Nimz, Haltern Am See DE
Patent application number | Description | Published |
---|---|---|
20080249250 | Copolymers Containing Lateral Carbamate Groups And Groups Which Can Be Activated With Actinic Radiation, Processes For Preparing Them, And Their Use - Copolymers (A) containing lateral, primary and/or secondary carbamate groups (a12) and groups (a31) which can be activated with actinic radiation, preparable by | 10-09-2008 |
Wilma Reidick, Bottrop DE
Patent application number | Description | Published |
---|---|---|
20100184733 | SKIN TREATMENT COMPOSITION - The invention discloses skin treatment compositions consisting essentially of a mixture of ceramides, cholesterol, free fatty acids—the mixture being able to mimic skin identical lamellar structures—and nonionic emulsifiers. These compositions are liquid and pumpable at room temperature which means that they can be incorporated easily into cosmetic formulations with no need for heating. Furthermore, the skin treatment compositions allow the stable inclusion of long-chain ceramides into oil-in-water emulsions as well as into water-in-oil emulsions. Inclusion of short chain ceramides that can act as dermatological regulators did not affect the lamellar lipid organization. The skin treatment compositions are claimed as well as their use in cosmetic and dermatological formulations. | 07-22-2010 |
Wilma Tamraz, San Jose, CA US
Patent application number | Description | Published |
---|---|---|
20140171646 | AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE - Amorphous and polymorphic of palonosetron hydrochloride are disclosed that can be characterized by X-ray powder diffraction patterns, thermal properties, purity and methods of manufacture. These forms of palonosetron hydrochloride can be produced from solution or by solid state interconversions. The forms can be used in pharmaceutical formulations: particularly preferred uses of these formulations are in prevention and treatment of nausea and emesis arising from chemotherapy or postoperative side effects. The forms can optionally be used as mixtures of the crystalline and/or amorphous forms. | 06-19-2014 |
20140308352 | COMPOSITIONS AND METHODS INVOLVING POLYMER, SOLVENT, AND HIGH VISCOSITY LIQUID CARRIER MATERIAL - Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed. | 10-16-2014 |
Wilma Thuer, Kulmbach DE
Patent application number | Description | Published |
---|---|---|
20110207799 | Compositions for Targeted Delivery of siRNA - The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers. | 08-25-2011 |
20110212861 | DIRECTED SYNTHESIS OF OLIGOPHOSPHORAMIDATE STEREOISOMERS - The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner. | 09-01-2011 |
20130245091 | Compositions for Targeted Delivery of siRNA - The present invention is directed compositions for targeted delivery of RNA interference (RNAi) polynucleotides to hepatocytes in vivo. Targeted RNAi polynucleotides are administered together with co-targeted delivery polymers. Delivery polymers provide membrane penetration function for movement of the RNAi polynucleotides from outside the cell to inside the cell. Reversible modification provides physiological responsiveness to the delivery polymers. | 09-19-2013 |
20140045719 | DIRECTED SYNTHESIS OF OLIGOPHOSPHORAMIDATE STEREOISOMERS - The trivalent phosphorous atom of a compound is reacted with a reagent in such a manner that a stable phosphate mimetic or a specifier is formed. Phosphoramidites with a phosphorous atom containing at least one hydroxyl residue which is provided with a protective group are reacted for this purpose with a free hydroxyl group: In the first synthesis cycle the hydroxyl group is linked to a solid support via a cleavable or non-cleavable linker. In further synthesis cycles the hydroxyl group is created by cleavage of the protective group from the growing oligomer. This results in formation of a phosphorous acid triester which is reacted with azides. By selecting suitable monomers for the synthesis which have a defined stereoconformation compounds of Formula 1 are produced in a stereocontrolled manner. | 02-13-2014 |
Wilma Timraz, San Jose, CA US
Patent application number | Description | Published |
---|---|---|
20100105724 | CRYSTALLINE AND AMORPHOUS FORMS OF PALONOSETRON HYDROCHLORIDE - Amorphous and polymorphic of palonosetron hydrochloride are disclosed that can be characterized by X-ray powder diffraction patterns, thermal properties, purity and methods of manufacture. These forms of palonosetron hydrochloride can be produced from solution or by solid state interconversions. The forms can be used in pharmaceutical formulations: particularly preferred uses of these formulations are in prevention and treatment of nausea and emesis arising from chemotherapy or postoperative side effects. The forms can optionally be used as mixtures of the crystalline and/or amorphous forms. | 04-29-2010 |
Wilma Verhagen-Kamerbeek, Pfeffingen CH
Patent application number | Description | Published |
---|---|---|
20130035603 | TROPONIN BASED RULE-IN AND RULE-OUT ALGORITHM OF MYOCARDIAL INFARCTION - The present invention relates to a method for diagnosing myocardial infarction in a subject presenting with chest pain. The method is based on the determination of an amount of a cardiac troponin in a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample. Moreover, the present invention envisages a method for ruling in myocardial infarction and a method for ruling out myocardial infarction. The said methods are also based on the determination of the amount of a cardiac troponin in a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample. | 02-07-2013 |
Wilma Wasco, Arlington, MA US
Patent application number | Description | Published |
---|---|---|
20100311726 | REDUCTION OF BETA-AMYLOID LEVELS BY TREATMENT WITH THE SMALL MOLECULE DIFFERENTIATION-INDUCING FACTOR - The present invention relates to novel uses for a family of small molecules, Differentiation-Inducing Factors (DIFs). It has been discovered that DIFs surprisingly can alter the metabolic processing of amyloid precursor protein (APP) and in turn reduce the level of secreted Aβ. The metabolic processing of other γ-secretase substrates normally present in cells (Notch and APLP1) is not affected when treated with DIF. The invention provides methods for reducing Aβ production in mammalian cells that express APP by administering DIF-I, DIF-2, DIF-3, a functionally equivalent analog and or any combination thereof. The invention also provides methods for treating and/or preventing Alzheimer's disease by preferentially reducing Aβ production. | 12-09-2010 |
Wilma Ziebuhr, Veitshochheim DE
Patent application number | Description | Published |
---|---|---|
20100286198 | Biofilm-Inhibiting Effect and Anti-Infective Activity of N,C- Linked Arylisoquinolines and the Use Thereof - Anti-infective and biofilm-inhibiting activities of aryl isoquinoline-derivatives of the general formulae 1 to 3 | 11-11-2010 |